1. Home
  2. Supports
  3. Featured Project Solutions
  4. Neurodegenerative Disease related Vaccine Solution

Neurodegenerative Disease Vaccine Solution

Creative Biolabs is dedicated to providing world-leading one-stop design and development services for Neurodegenerative Disease Vaccines. We focus on complex neurological disorders such as Parkinson's Disease (PD) and Alzheimer's Disease (AD), accelerating our clients' transition from proof-of-concept to pre-clinical vaccine candidates through precise epitope screening, innovative adjuvant delivery systems, and high-safety toxicity assessment.

Talk To Our Vaccine Experts View Services
Overall solution framework for neurodegenerative disease vaccine development.

Concept and Core Challenges of Neurodegenerative Disease Vaccine

Neurodegenerative Disease Vaccines represent the application of active immunization strategies in neuroscience. They aim to induce the body to produce specific antibodies against disease-related pathological proteins (such as Aβ, Tau, α-Synuclein), thereby clearing or neutralizing these toxic aggregates and preventing neuronal damage, ultimately achieving disease modification or prevention.

Core Issues Requiring Attention in this Field:

How to design antigens (peptides, recombinant proteins, or DNA/RNA) to ensure high antibody titers and strong affinity, while specifically targeting the pathological forms of the disease (e.g., oligomers, not monomers).

Antibodies induced by the vaccine must efficiently cross the Blood-Brain Barrier (BBB) to reach the site of action (brain parenchyma), which is a key limiting factor for therapeutic efficacy.

The critical challenge is to differentiate between pathological proteins (e.g., misfolded or aggregated proteins) and normal physiological proteins to avoid inducing autoimmune reactions against normal proteins, such as autoimmune meningoencephalitis observed in some past clinical trials.

What Core Problems Do We Help Clients Solve?

Creative Biolabs focuses on solving three major pain points in neurodegenerative disease vaccine development and provides customized solutions.

Precise Target and Antigen Design Optimization

  • Validation and Confirmation of Emerging Pathological Targets: Verifying new neurodegenerative disease-related targets through in vitro models and biomarker analysis.
  • AI-Assisted Pathological Epitope Prediction: Utilizing advanced bioinformatics tools and AI algorithms to precisely identify and design minimal, highly specific antigens targeting disease-specific pathological conformations.
  • High-Quality Immunogen Synthesis: Providing high-purity, high-stability customized synthesis services for peptide, recombinant protein, or nucleic acid (DNA/RNA) antigens.

High-Efficacy and Low-Risk Adjuvant Strategies

  • Adjuvant Innovative Adjuvant Library Screening: Offering diverse novel adjuvants (e.g., TLR agonists, VLPs) and customized matching and formulation optimization based on antigen characteristics.
  • Biased Immune Response Modulation: Designing adjuvant strategies to promote Th2-biased immune responses, which increases protective antibody titers and effectively avoids Th1-mediated inflammation and autoimmune risks.
  • Vaccine Formulation Stability Optimization: Ensuring the stability and bioavailability of the final vaccine formulation, meeting the requirements for subsequent storage and delivery.

Preclinical Acceleration

  • Comprehensive Animal Models for Neurodegenerative Diseases: Providing established transgenic and chemically-induced animal models for PD, AD, HD, etc., for comprehensive in vivo efficacy testing.
  • Integrated In Vivo Safety and Efficacy Assessment: Conducting systematic toxicology and tolerability tests, along with behavioral and neuropathological indicators, to comprehensively evaluate the vaccine's efficacy in clearing pathological proteins and improving symptoms.

Our Services for Neurodegenerative Disease Vaccine

Parkinson's Disease (PD)

Antigen design targeting the pathological aggregates of α-Synuclein.

Alzheimer's Disease (AD)

Epitope-focused vaccine design targeting Aβ and/or Tau proteins.

Huntington's Disease (HD)

Immune strategy for degradation and clearance of mutant huntingtin protein (mHTT) N-terminal region.

Lewy Body Disease (LBD)

Similar to PD, focusing on α-Synuclein aggregates in the cerebral cortex and limbic system.

Multiple System Atrophy (MSA)

Targeting oligomeric α-Synuclein to block pathological spread in glial cells.

Prion Disease

Antibody induction strategy against prion protein (PrPSc) to block its conformational change.

Primary Progressive Aphasia (PPA)

Customized vaccine design targeting Tau or Aβ protein pathology involved in PPA subtypes.

Core Technology Platforms

High-Throughput Epitope Focusing Screening Platform for the vaccine.

High-Throughput Epitope Focusing Screening Platform

Combining bioinformatics analysis and peptide library synthesis to quickly identify and screen the minimal pathological epitopes capable of inducing highly specific antibodies.

Innovative Adjuvant Delivery Technology for enhancing vaccine efficacy.

Adjuvant Innovative Adjuvant Delivery Technology

Possessing a diverse library of novel adjuvants (e.g., TLR agonists, VLP) for customized formulation to achieve efficient immune activation and safety optimization.

Fully Humanized Immune Response Simulation System for the vaccine.

Fully Humanized Immune Response Simulation System

Utilizing humanized mouse models and in vitro humanized immune cell lines to pre-assess the potential immunogenicity and toxicity of the vaccine in humans, thereby mitigating clinical risk.

Multi-Modal Neuropathological Assessment Technology post-vaccine.

Multi-Modal Neuropathological Assessment Technology

Combining brain tissue immunohistochemistry, Western Blot, ELISA, and advanced in vivo imaging techniques to precisely evaluate the vaccine's target binding, aggregate clearance, and behavioral improvement in animal models.

Neurodegenerative Disease related Vaccine R&D Workflow

Antigen Discovery & Formulation Optimization

The process involves Target Confirmation & Precise Epitope Identification via structural biology and bioinformatics, followed by Antigen Design & Synthesis of customized peptides or recombinant proteins, and concludes with Adjuvant Screening & Stable Formulation to create a highly efficacious vaccine.

In Vitro Immunogenicity Assessment

Testing the vaccine's immunogenicity in in vitro immune cell models to evaluate its potential to induce antibody production and cytokine responses.

Integrated Preclinical Safety & Efficacy Validation

The final stage of vaccine development involves In Vivo Safety Testing in non-human primate or rodent models to assess toxicology and rule out autoimmune risks, followed by In Vivo Efficacy Testing to comprehensively evaluate the vaccine's ability to clear pathological proteins and improve symptoms in animal models of neurodegenerative diseases like PD and AD.

Project Data Management & Professional Reporting

The concluding steps involve Rigorously managing, statistically analyzing, and interpreting all preclinical experimental data to generate systematic professional reports that comprehensively summarize the vaccine's physicochemical properties, immunological characteristics, and preclinical performance.

Partner with Creative Biolabs Now!

Creative Biolabs Service Benefits

Patented Adjuvant Technology Platform

We possess a leading-edge library of novel adjuvants capable of inducing safer, higher-proportion Th2-biased immune responses, effectively mitigating risks such as autoimmune encephalitis.

AI-Assisted Antigen Design

Combining artificial intelligence algorithms for protein structure prediction and modeling to precisely locate pathology-specific epitopes, significantly boosting the success rate and specificity of vaccine design.

Extensive CNS Disease Model Expertise

Utilizing established transgenic animal model platforms for PD, AD, and HD, ensuring the reliability and authenticity of in vivo efficacy data.

Efficient and Flexible Delivery

Modular service design allows for flexible combination based on specific client needs (e.g., only adjuvant screening or antigen optimization), ensuring rapid response to project requirements.

Creative Biolabs' service benefits in neurodegenerative disease vaccine field.

Case Study

α-Synuclein-Based Peptide Epitope Vaccine for Parkinson's Disease

Background

A study aimed to develop an α-synuclein (α-syn)-based peptide epitope vaccine to alleviate Parkinson's Disease (PD) pathology, as α-syn accumulation causes dopaminergic neuron loss and motor dysfunction, and immunization shows promise for neurodegenerative diseases.

Solution

Three vaccines (non-carrier, OVA-carrier, KLH-carrier) were designed via in silico screening (PEP1 epitope). α-syn-induced PD mice (C57BL/6N) were immunized; motor function (open field/rotarod tests), α-syn levels, dopamine markers, and neuroinflammation were assessed via Western blot, ELISA, and immunofluorescence.

Result

Vaccines, especially OVA/KLH-carrier, improved motor function, increased spleen/plasma IgG, reduced plasma IL-10, decreased α-syn, enhanced dopamine markers (TH/DAT/VMAT2) and autophagy, and lowered glial activation (GFAP/Iba-1) and pro-inflammatory cytokines (TNF-α/IL-1β), supporting PD prevention potential.

In Silico Modeling for α-syn-based peptide epitope vaccine design.

In Silico Modeling for α-syn-based Peptide Epitope Vaccine Design.
Park, Jun Sung, et al. "Immunization effects of a novel α-synuclein-based peptide epitope vaccine in Parkinson's disease-associated pathology." Vaccines 11.12 (2023): 1820. Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/vaccines11121820.

Customer Reviews

"The Creative Biolabs team delivered outstanding results on our Alzheimer's disease vaccine project. The Aβ vaccine peptide they designed showed excellent immunogenicity, with minimal side effects in animal models. The project was delivered on time, with reliable data—they are our preferred partner in neuro-immunology."

- Dr. Han

Biotech CEO

"We collaborated on a Parkinson's disease vaccine targeting α-Synuclein. Their innovative adjuvant selection platform helped us find the perfect combination to effectively induce a protective antibody response. Their neuro-immunology expertise is unquestionable; highly recommended!"

- Prof. Rodriguez

University Research Center

"From concept to preclinical candidate, Creative Biolabs provided seamless service. Their expertise helped us navigate potential autoimmune risks, allowing our Huntington's disease vaccine project to advance quickly and exceed expectations."

- M. Dubois

R&D Director

FAQs of Neurodegenerative Disease Vaccine Service

What molecules do neurodegenerative disease vaccines primarily target?

They mainly target pathological aggregated proteins associated with disease progression, such as β-amyloid and Tau proteins for Alzheimer's Disease (AD), α-Synuclein for Parkinson's Disease (PD) and Lewy Body Dementia (LBD), and mutant huntingtin protein (mHTT) for Huntington's Disease (HD).

What is the difference between active and passive immunization in neurodegenerative disease therapy?

Active immunization (vaccines) stimulates the body to produce its own antibodies after antigen injection, offering a long-lasting effect but slower onset. Passive immunization involves directly injecting externally produced antibodies, offering a fast onset but requiring repeated administration and higher cost. Our services primarily focus on the active immunization strategy.

How does your company balance vaccine immunogenicity with safety?

We use Epitope Focusing Technology to target only specific pathological epitopes, avoiding the activation of immune responses against normal proteins. Concurrently, by screening novel adjuvants, we promote Th2 helper T-cell responses (anti-inflammatory) over Th1 responses (pro-inflammatory), thereby enhancing efficacy and reducing autoimmune risk.

Does your vaccine design service include the screening of novel adjuvants?

Yes, adjuvant screening is a core component of our services. We offer customized screening of a novel adjuvant library to ensure the antigen is combined with the optimal adjuvant formulation for maximum immune potency and safety.

Do you have specialized platforms for vaccine development against rare neurodegenerative diseases?

Absolutely. We provide fully customized antigen design services. Even for rare diseases such as Primary Progressive Aphasia (PPA) or Multiple System Atrophy (MSA), we can design highly specific vaccine candidates based on known or hypothesized pathological mechanisms.

Act Now and Lead the New Era of Neuro-Immunotherapy

The treatment of neurodegenerative diseases urgently requires innovative breakthroughs, and active immunization vaccines represent enormous potential for cure. By choosing Creative Biolabs, you gain access to a world-class vaccine design platform, high-success-rate development experience for Neurodegenerative Disease Vaccines, and the full support of a senior neuro-immunology expert team.

Start Your Project Now!

Featured Products for Vaccine Development

Antigen Products

Antibody Products

Adjuvant Products

Delivery System related Products

Array Kits

Cell Culture Medium Products

Featured Resources

Reference image of vaccine-resources-1, containing materials relevant to vaccine research and development.

Download Resources

Visual of vaccine-literature-1, representing academic or technical literature focused on vaccine studies.

Literature Center

Cover or promotional image for vaccine-podcast-1, a podcast discussing topics related to vaccines.

Podcast

Online Inquiry

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


(USA)



Vaccine - Creative Biolabs
ISO 9001 Certified - Creative Biolabs Quality Management System
Shopping Basket